Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pain 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1Breast Diseases 1Agnosia 1

Interventions

Methods 5Surveys and Questionnaires 3Radiosurgery 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Early Intervention, Educational 3Brachytherapy 3Biopsy 3aflibercept 2Vaccines, Synthetic 2Vaccines 2Trastuzumab 2Sentinel Lymph Node Biopsy 2Radiotherapy 2Psychiatric Rehabilitation 2Papillomavirus Vaccines 2Palliative Care 2Counseling 2Cisplatin 2tremelimumab 1tipifarnib 1pembrolizumab 1oncogene protein E7, Human papillomavirus type 16 1nanocis 1fludarabine phosphate 1fludarabine 1entinostat 1durvalumab 1alovudine 1aldesleukin 1Wound Closure Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Vulvar Neoplasms × Codeine × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡